文献速递肿瘤 PET/CT甲状腺核医学

18F-rhPSMA-7.3 PET 用于原发性前列腺癌显像及经组织病理学验证的不良中危至极高危患者术前 N 分期效能

Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.
PubMed 文献 · J Nucl Med · 2022-01-06

回顾性纳入 279 例原发性前列腺癌患者行 18F-rhPSMA-7.3 PET/CT 分期,其中 83 例后续行前列腺切除加淋巴结清扫构成效能队列。PET 对盆腔淋巴结转移的患者水平敏感度 66.7%、特异度 96.6%、准确率 88.0%,均高于形态学影像的 37.5%、91.5%、75.9%。读者间一致性 Fleiss κ 为 0.54,高于形态学影像的 0.24。

要点

  • 分期队列中 18F-rhPSMA-7.3 PET 阳性率:局部 98.6%、盆腔淋巴结 38.0%、盆腔外淋巴结 16.5%、骨转移 23.3%、内脏转移 1.8%。
  • 效能队列组织病理学证实 24/83 例(29%)存在淋巴结转移,累及 48/420(11%)切除模板和 33/166(19.9%)半骨盆模板。
  • 18F-rhPSMA-7.3 PET 患者水平盆腔淋巴结分期敏感度、特异度、准确率均高于形态学影像,读者间一致性也更高。

核心结论

  • 18F-rhPSMA-7.3 PET 对新诊断前列腺癌的原发 N 分期诊断效能优于形态学影像,读者间变异更小,并能较好区分原发肿瘤活性与膀胱背景活性。
  • 随着美国国家综合癌症网络(NCCN)风险组升高,前列腺外肿瘤病灶的出现频率增加。

研究设计与样本

  • 回顾性识别 279 例原发性前列腺癌患者行 18F-rhPSMA-7.3 PET/CT,构成分期队列。
  • 其中 83/279 例后续行前列腺切除加淋巴结清扫且未经先前治疗,构成效能队列。
  • 盆腔淋巴结受累由 3 名设盲独立中心读者回顾性评估,分析采用多数规则。
  • 标准手术野分别对 PET 与形态学影像独立进行 5 分制评分,结果与组织病理学按患者、左右侧及模板水平比较。

主要发现

  • 分期队列中 18F-rhPSMA-7.3 PET 阳性患者数分别为局部 275/279(98.6%)、盆腔淋巴结 106/279(38.0%)、盆腔外淋巴结 46/279(16.5%)、骨转移 65/279(23.3%)、内脏转移 5/279(1.8%)。
  • 效能队列组织病理学显示淋巴结转移见于 24/83 例(29%),位于 48/420(11%)切除模板和 33/166(19.9%)半骨盆模板。
  • 患者水平盆腔淋巴结转移的敏感度、特异度、准确率:18F-rhPSMA-7.3 PET 分别为 66.7%(95%CI 44.7%-83.6%)、96.6%(95%CI 87.3%-99.4%)、88.0%(95%CI 78.5%-93.8%);形态学影像分别为 37.5%(95%CI 19.6%-59.2%)、91.5%(95%CI 80.6%-96.8%)、75.9%(95%CI 65.0%-84.3%)。
  • 患者水平读者间一致性 Fleiss κ:18F-rhPSMA-7.3 PET 为 0.54(95%CI 0.47-0.62),形态学影像为 0.24(95%CI 0.17-0.31)。
  • 局部肿瘤与邻近低尿液示踪剂滞留之间的平均 SUV 比值为 6.6(95%CI 5.2-8.1),显示高图像对比度。

关键数值与推荐

  • 患者水平盆腔淋巴结转移敏感度:18F-rhPSMA-7.3 PET 66.7%(95%CI 44.7%-83.6%)vs 形态学影像 37.5%(95%CI 19.6%-59.2%)。
  • 患者水平盆腔淋巴结转移特异度:18F-rhPSMA-7.3 PET 96.6%(95%CI 87.3%-99.4%)vs 形态学影像 91.5%(95%CI 80.6%-96.8%)。
  • 患者水平盆腔淋巴结转移准确率:18F-rhPSMA-7.3 PET 88.0%(95%CI 78.5%-93.8%)vs 形态学影像 75.9%(95%CI 65.0%-84.3%)。
  • 读者间一致性 Fleiss κ:18F-rhPSMA-7.3 PET 0.54(95%CI 0.47-0.62)vs 形态学影像 0.24(95%CI 0.17-0.31)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-rhPSMA-7.3, the lead compound of a new class of radiohybrid prostate-specific membrane antigen (rhPSMA) ligand, is currently in phase III trials for prostate cancer (PCa) imaging. Here, we describe our experience in primary PCa staging. Methods: We retrospectively identified 279 patients with primary PCa who underwent 18F-rhPSMA-7.3 PET/CT (staging cohort). A subset of patients (83/279) subsequently underwent prostatectomy with lymph node (LN) dissection without prior treatment (efficacy cohort). The distribution of tumor lesions was determined for the staging cohort and stratified by National Comprehensive Cancer Network risk score. Involvement of pelvic LNs was assessed retrospectively by 3 masked independent central readers, and a majority rule was used for analysis. Standard surgical fields were rated on a 5-point scale independently for PET and for morphologic imaging. Results were compared with histopathologic findings on a patient, right-vs.-left, and template basis. Results: For the staging cohort, 18F-rhPSMA-7.3 PET was positive in 275 of 279 (98.6%), 106 of 279 (38.0%), 46 of 279 (16.5%), 65 of 279 (23.3%), and 5 of 279 (1.8%) patients for local, pelvic nodal, extrapelvic nodal, metastatic bone, and visceral metastatic disease, respectively. In the efficacy cohort, LN metastases were present in 24 of 83 patients (29%) and were located in 48 of 420 (11%) resected templates and in 33 of 166 (19.9%) hemipelvic templates in histopathology. The majority vote results showed that patient-level sensitivity, specificity, and accuracy for pelvic nodal metastases were 66.7% (95% CI, 44.7%-83.6%), 96.6% (95% CI, 87.3%-99.4%), and 88.0% (95% CI, 78.5%-93.8%), respectively, for 18F-rhPSMA-7.3 PET and 37.5% (95% CI, 19.6%-59.2%), 91.5% (95% CI, 80.6%-96.8%), and 75.9% (95% CI, 65.0%-84.3%), respectively, for morphologic imaging. 18F-rhPSMA-7.3 showed higher interobserver agreement than morphologic imaging (patient-level Fleiss κ = 0.54 [95% CI, 0.47-0.62] vs. 0.24 [95% CI, 0.17-0.31]). A mean SUV ratio of 6.6 (95% CI, 5.2-8.1) documented a high image contrast between local tumors and adjacent low urinary tracer retention. Conclusion: 18F-rhPSMA-7.3 PET offers diagnostic performance superior to morphologic imaging for primary N-staging of newly diagnosed PCa, shows lower interreader variation, and offers good distinction between primary-tumor activity and bladder background activity. With increasing National Comprehensive Cancer Network risk group, an increasing frequency of extraprostatic tumor lesions was observed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Langbein T, Wang H, Rauscher I, et al. Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. J Nucl Med. 2022. PMID: 34992154. doi:10.2967/jnumed.121.263440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。